Enzalutamide (Xtandi®) pre chemotherapy

Assessment Status Assessment process complete
Drug Enzalutamide
Brand Xtandi®
Indication First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Assessment Process
Rapid review commissioned 05/11/2014
Rapid review completed 22/12/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 09/04/2015
NCPE assessment completed 22/06/2015
NCPE assessment outcome Reimbursement Not Recommended at the submitted price.

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.